Category - Developments

Proteostasis Therapeutics’ (NASDAQ: PTI) PTI-428 has been granted orphan drug designation by the European Medicines Agency (EMA) for the treatment of cystic fibrosis (CF). CF is caused by a mutation in cystic fibrosis...

Verona Pharma (NASDAQ:VRNA) initiated a Phase 2 trial of its metered-dose inhaler (MDI) formulation of ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Ensifentrine inhibits...

Titan Pharmaceuticals (NASDAQ:TTNP) signed a pharmacy services agreement with Southside Specialty Pharmacy, further expanding access to treatment with Probuphine (buprenorphine) implant, Titan’s unique maintenance...

Zenabis Global (TSX:ZENA) received an industrial hemp production license from Health Canada. “This is the second cultivation license we have received from Health Canada this year, and is another important step...

Epizyme (NASDAQ:EPZM) submitted an NDA to the FDA for tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma. Epithelioid sarcoma is a very rare soft tissue sarcoma. Tazemetostat is a small...

REGENXBIO (NASDAQ:RGNX) has completed dosing in its Phase 1/2a trial of RGX-314 for the treatment of wet age-related macular degeneration (AMD). RGX-314 uses REGENXBIO’s proprietary NAV gene delivery platform to...

Zenabis Global (TSX:ZENA) posted net revenue of $11.6-million from its cannabis and propogation segment for the first quarter of 2019, up from $3.4-million in the fourth quarter of 2018, which included only its cannabis...

BriaCell Therapeutics’ (TSXV:BCT; OTCQB:BCTXF) clinical findings were published at the 2019 American Society of Clinical Oncology (ASCO) annual meeting proceedings, a supplement to the Journal of Clinical Oncology...

Closely-held Scientus Pharma received authorization under Health Canada’s cannabis regulations for the sale of cannabis oils and capsules for medical purposes. The company previously obtained its Health Canada license...

OncoSec Medical (NASDAQ:ONCS) dosed the first patient in a trial assessing a triple drug combination, which includes OncoSec’s TAVO, in patients with unresectable squamous cell carcinoma head and neck (SCCHN) cancer...